Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results

Journal of Clinical Microbiology

Volumn 50, Issue 4, 2012, Pages 1303-1307

  Kaltsas, Anna ^a   Simon, Matt ^b   Unruh, Larissa H ^c   Son, Crystal ^a   Wroblewski, Danielle ^d   Musser, Kimberlee A ^d   Sepkowitz, Kent ^a   Babady, N Esther ^a   Kamboj, Mini ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Mailman School of Public Health ^*  (United States)

^d WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL STRAIN; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CYTOTOXIN ASSAY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; LENGTH OF STAY; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; BACTERIAL TOXINS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FALSE NEGATIVE REACTIONS; FECES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

CLOSTRIDIUM DIFFICILE;

EID: 84858588687     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05711-11     Document Type: Article

References (22)

1. Babady NE, et al. 2010. Evaluation of the Cepheid Xpert Clostridium difficile epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J. Clin. Microbiol. 48:4519-4524.
2. Bidet P, et al. 2000. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J. Clin. Microbiol. 38:2484-2487. (Pubitemid 30487377)
3. Blossom DB, McDonald LC. 2007. The challenges posed by reemerging Clostridium difficile infection. Clin. Infect. Dis. 45:222-227. (Pubitemid 47041014)
4. Cohen SH, et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
5. Hess DR. 2004. Retrospective studies and chart reviews. Resp. Care 49:1171-1174.
6. Kelly CP, LaMont JT. 2008. Clostridium difficile - more difficult than ever. N. Engl. J. Med. 359:1932-1940.
7. Kvach EJ, Ferguson D, Riska PF, Landry ML. 2010. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J. Clin. Microbiol. 48:109-114.
8. Labbe A-C, et al. 2008. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob. Agents Chemother. 52:3180-3187.
9. Louie TJ, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
10. McDonald LC, et al. 2007. Recommendations for surveillance of Clostridium difficile-associated disease. Infect. Control Hosp. Epidemiol. 28:140-145. (Pubitemid 46374153)
11. Miller M, et al. 2010. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50:194-201.
12. Novak-Weekley SM, et al. 2010. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J. Clin. Microbiol. 48:889-893.
13. O'Connor JR, Johnson S, Gerding DN. 2009. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136:1913-1924.
14. Pepin J, Valiquette L, Cossette B. 2005. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037-1042.
15. Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. 2008. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J. Clin. Microbiol. 46:1996-2001. (Pubitemid 351831833)
16. Spigaglia P, Mastrantonio P. 2002. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J. Clin. Microbiol. 40:3470-3475. (Pubitemid 34977470)
17. Stamper PD, et al. 2009. Evaluation of a new commercial TaqMan PCR assay for direct detection of the Clostridium difficile toxin B gene in clinical stool specimens. J. Clin. Microbiol. 47:3846-3850.
18. Stata Corp. 2007. Stata Statistical Software, release 10. Stata Corp., College Station, TX.
19. Tenover FC, et al. 2010. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J. Clin. Microbiol. 48:3719-3724.
20. Warny M, et al. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084. (Pubitemid 41338761)
21. Wolk, DM, Hayden, RT. 2011. Quantitative molecular methods, p 85. In D Persing, et al. (ed), Molecular microbiology. Diagnostic principles and practice, 2nd ed. American Society of Microbiology, Washington, DC.
22. Wroblewski D, et al. 2009. Rapid molecular characterization of Clostridium difficile and assessment of populations of C. difficile in stool specimens. J. Clin. Microbiol. 47:2142-2148.